SEC Filing Summary: Carlyle Group Inc. (Form 13F)
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Carlyle Group Inc. for the reporting period ending December 31, 2024. The document discloses the investment manager's holdings in equity securities as of the quarter-end date. It does not contain financial performance data for Carlyle Group Inc. itself, but rather a snapshot of its portfolio positions.
Key Financial Metrics and Portfolio Composition
The filing lists 26 specific equity positions. The total aggregate value of these disclosed holdings is approximately $167.5 million. The portfolio is heavily weighted toward the biotechnology and healthcare sectors, with significant exposure to emerging growth companies.
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Standardaero Inc | 6,675,862 | $3,866,903,077 | Sole |
| Soleno Therapeutics Inc | 1,375,646 | $61,752,749 | Sole |
| Phathom Pharmaceuticals Inc | 3,496,808 | $28,394,081 | Sole |
| Pony Ai Inc | 2,362,447 | $33,901,116 | Shared |
| Weride Inc | 3,423,023 | $48,538,462 | Shared |
| Getty Images Holdings Inc | 8,684,599 | $18,758,735 | Sole |
| Adicet Bio Inc | 2,948,718 | $2,843,449 | Sole |
| Complete Solaria Inc | 1,984,619 | $3,552,468 | Sole |
Note: The value listed for Standardaero Inc ($3.86 billion) appears anomalously high relative to the share count and other holdings in this table, suggesting a potential data formatting error in the source text or a specific valuation method not detailed here. All other values are consistent with typical market prices for the listed shares.
Material Changes and Observations
As this is a static snapshot of holdings, no period-over-period changes (e.g., purchases vs. sales) can be calculated from this single document. However, the composition indicates a strategic focus on:
- Biotechnology: Significant positions in Adicet Bio, Exicure, Hillevax, Jasper Therapeutics, Onkure, Phathom, Q32 Bio, Soleno, Spruce Biosciences, and Spyre Therapeutics.
- Technology & AI: Holdings in Pony Ai and Weride Inc (autonomous driving).
- Real Estate & Services: Positions in CubeSmart, Invitation Homes, and Getty Images.
Guidance, Risks, and Contingencies
The filing contains no management commentary, forward-looking guidance, or specific risk disclosures beyond the standard SEC disclaimer stating that the Commission has not reviewed the information for accuracy. The "Other" column indicates some positions involve shared voting authority (e.g., Pony Ai, Weride, Smart Sh Global), implying co-investment structures or joint management arrangements.
Investor Verification Checklist
- Data Anomaly: Verify the reported value of Standardaero Inc ($3.86 billion) against the share count (6.6M) and current market price, as this figure is disproportionately large compared to the rest of the portfolio.
- Portfolio Scope: Confirm whether this table represents the entirety of Carlyle's 13F report or a subset, as the total value (~$167M excluding the Standardaero anomaly) is relatively small for a firm of Carlyle's size.
- Voting Rights: Review the "Shared" voting authority entries to understand the extent of co-investment or joint control in specific positions.
- Valuation Method: Check if the "Value" column reflects fair market value or a different accounting basis, particularly for private-to-public transition companies like Pony Ai and Weride.